Skip Navigation


Rheumatology Advance Access originally published online on August 18, 2008
Rheumatology 2008 47(10):1589-1590; doi:10.1093/rheumatology/ken344
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
47/10/1589    most recent
ken344v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kobelt, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kobelt, G.
Related Collections
Right arrow Health Economics
Right arrow Pharmacology
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance

G. Kobelt

European Health Economics, Mulhouse, France

Correspondence to: G. Kobelt, European Health Economics, 40 rue Jean Monnet, F - 68200 Mulhouse, France. E-mail: gisela.kobelt@he-europe.com

The first 10% of the full text of this article appears below.

SIR, The recent editorial by Wailoo et al. [1] on cost-effectiveness evidence of TNF-inhibitors in AS is incorrect and worrying in several respects.

First, the critique of the paper by Kobelt et al. [2] is factually wrong. The numbers cited by Wailoo and colleagues are nowhere to be found in this publication, and . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
Editor
Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance: Editor's note
Rheumatology, October 1, 2008; 47(10): 1590 - 1591.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
A. Wailoo, N. Bansback, and J. Chilcott
Comment on: Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidance: reply
Rheumatology, October 1, 2008; 47(10): 1590 - 1590.
[Full Text] [PDF]